Kiora Pharmaceuticals INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Kiora Pharmaceuticals CFO Melissa Tosca reported a transaction involving the sale of common stock.
NASDAQ
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a transaction involving the sale of 1,869 shares of common stock.
NASDAQ
Director Carmine N. Stengone was granted 25,000 stock options under the company's 2024 Equity Incentive Plan.
NASDAQ
Director Aron Shapiro was granted 25,000 stock options in Kiora Pharmaceuticals under the 2024 Equity Incentive Plan.
NASDAQ
Kiora Pharmaceuticals Director Erin Parsons received 25,000 stock options with an exercise price of $2.63, vesting fully by June 10, 2027.
NASDAQ
Director David Hollander received 25,000 stock options with an exercise price of $2.63 as part of the company's equity incentive plan.
NASDAQ
Director Praveen Tyle was granted 40,000 stock options in Kiora Pharmaceuticals under the 2024 Equity Incentive Plan.
NASDAQ
Kiora Pharmaceuticals CFO Melissa Tosca reported a transaction involving the sale of common stock.
NASDAQ
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a transaction involving the sale of common stock.
NASDAQ
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a transaction involving the sale of 1,906 shares of common stock.
NASDAQ
Kiora Pharmaceuticals' Chief Development Officer, Eric Joseph Daniels, disposed of 238 shares of common stock to cover tax obligations.
NASDAQ
Kiora Pharmaceuticals' President and CEO, Brian M. Strem, reported the disposition of 238 common shares for tax obligations related to restricted stock vesting.
NASDAQ
Melissa Tosca, CFO of Kiora Pharmaceuticals, reports the acquisition of restricted stock and stock options, as per a recent SEC Form 4 filing.
NASDAQ
Chief Development Officer Eric Daniels reports acquisition of restricted stock and stock options in Kiora Pharmaceuticals.
NASDAQ
Brian M. Strem, CEO of Kiora Pharmaceuticals, reports acquisition of common stock and stock options.
NASDAQ
Director Aron Shapiro acquired 20,000 stock options in Kiora Pharmaceuticals, Inc. on April 1, 2025, according to a Form 4 filing.
NASDAQ
Erin Parsons, a director at Kiora Pharmaceuticals, acquired options to purchase 20,000 shares of common stock on April 1, 2025.
NASDAQ
Director David Hollander receives options to purchase 20,000 shares of Kiora Pharmaceuticals stock, exercisable starting April 1, 2026.
NASDAQ
Director Praveen Tyle receives options to purchase 30,000 shares of Kiora Pharmaceuticals stock, according to a Form 4 filing.
NASDAQ
Carmine N. Stengone, a director of Kiora Pharmaceuticals, acquired stock options for 20,000 shares on April 1, 2025.
NASDAQ
Lisa Walters-Hoffert, a director of Kiora Pharmaceuticals, acquired stock options for 20,000 shares on April 1, 2025.
NASDAQ
Director Carmine N. Stengone of Kiora Pharmaceuticals Inc. [KPRX] purchased 1,250 shares of common stock at an average price of $3.68 on September 11, 2024.
NASDAQ
Director Aron Shapiro indirectly acquired 3,000 shares of Kiora Pharmaceuticals through The Shapiro Family Irrevocable Trust on September 10, 2024.
NASDAQ
Director Lisa Walters-Hoffert of Kiora Pharmaceuticals, Inc. reports purchasing 1,250 shares of common stock at an average price of $3.86.
NASDAQ
Director Praveen Tyle of Kiora Pharmaceuticals Inc. (KPRX) recently purchased 5,000 shares of common stock at $3.96 per share.
NASDAQ
Melissa Tosca, CFO of Kiora Pharmaceuticals, recently purchased 2,000 shares of the company's common stock at an average price of $3.21.
NASDAQ
Brian Strem, CEO of Kiora Pharmaceuticals, reports the acquisition of restricted stock and stock options under the company's 2024 Equity Incentive Plan.
NASDAQ
Melissa Tosca, CFO of Kiora Pharmaceuticals, reports the acquisition of restricted stock and stock options under the company's 2024 Equity Incentive Plan.
NASDAQ
Eric Joseph Daniels, Chief Development Officer of Kiora Pharmaceuticals, received stock options and a restricted stock grant on July 1, 2024, according to a Form 4 filing.
NASDAQ
Carmine N. Stengone, a director of Kiora Pharmaceuticals, acquired stock options on July 1, 2024, under the company's 2024 Equity Incentive Plan.